A new in vitro method to predict in vivo photoprotection of skin hyperpigmentation induced by visible light.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
revised:
05
01
2022
received:
08
11
2021
accepted:
04
02
2022
pubmed:
1
3
2022
medline:
14
5
2022
entrez:
28
2
2022
Statut:
ppublish
Résumé
Ultraviolet radiation is the main cause of skin pigmentation, but more recently visible light has been shown to be an important contributor especially in melano-competent subjects. Photoprotection from visible light can improve several hyperpigmentation disorders. Recently, a visible light photoprotection assessment method has been proposed based on in vivo pigmentation; the visible light photoprotection factor (VL-PF) is determined by assessment of the change in colorimetry parameter ITA over several days measured using a chromameter. Although in vivo methods remain the most representative of real life, in vitro methods are more suited to screening sunscreen formulations. The aim of this study was to evaluate the correlation between in vivo and in vitro methods in assessing protection against visible light induced pigmentation. We first analysed the in vitro protective properties of the 10 commercially available sunscreens using transmission measurements in the visible spectrum. Then, we performed a monocentric, double-blind, randomized controlled study with intra-individual comparisons in 20 healthy subjects and measure the VL-PF in vivo of those sunscreens. The correlation between the VL-PF and the percentage of blocked light was evaluated using the coefficient of determination R A strong significant correlation was demonstrated between in vivo visible light protection factor and in vitro transmittance measurements, with the highest correlation factor at 420 nm and in the spectrum covering from 400 to 469 nm. Transmittance measurements were found to be a good predictive tool to evaluate sunscreen visible light photoprotection efficacy and could be used to select formulations for final in vivo testing.
Sections du résumé
BACKGROUND
BACKGROUND
Ultraviolet radiation is the main cause of skin pigmentation, but more recently visible light has been shown to be an important contributor especially in melano-competent subjects. Photoprotection from visible light can improve several hyperpigmentation disorders. Recently, a visible light photoprotection assessment method has been proposed based on in vivo pigmentation; the visible light photoprotection factor (VL-PF) is determined by assessment of the change in colorimetry parameter ITA over several days measured using a chromameter. Although in vivo methods remain the most representative of real life, in vitro methods are more suited to screening sunscreen formulations.
OBJECTIVE
OBJECTIVE
The aim of this study was to evaluate the correlation between in vivo and in vitro methods in assessing protection against visible light induced pigmentation.
METHODS
METHODS
We first analysed the in vitro protective properties of the 10 commercially available sunscreens using transmission measurements in the visible spectrum. Then, we performed a monocentric, double-blind, randomized controlled study with intra-individual comparisons in 20 healthy subjects and measure the VL-PF in vivo of those sunscreens. The correlation between the VL-PF and the percentage of blocked light was evaluated using the coefficient of determination R
RESULTS
RESULTS
A strong significant correlation was demonstrated between in vivo visible light protection factor and in vitro transmittance measurements, with the highest correlation factor at 420 nm and in the spectrum covering from 400 to 469 nm.
CONCLUSION
CONCLUSIONS
Transmittance measurements were found to be a good predictive tool to evaluate sunscreen visible light photoprotection efficacy and could be used to select formulations for final in vivo testing.
Identifiants
pubmed: 35224781
doi: 10.1111/jdv.18034
pmc: PMC9314032
doi:
Substances chimiques
Sunscreening Agents
0
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
922-926Subventions
Organisme : NAOS
Informations de copyright
© 2022 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Références
Pigment Cell Melanoma Res. 2018 Sep;31(5):649-652
pubmed: 29436173
J Invest Dermatol. 2021 Nov;141(11):2569-2576
pubmed: 34112516
Photodermatol Photoimmunol Photomed. 2017 Sep;33(5):260-266
pubmed: 28602025
Int J Cosmet Sci. 2018 Dec;40(6):589-595
pubmed: 30428143
J Am Acad Dermatol. 2015 Jan;72(1):189-90.e1
pubmed: 25443629
Photodermatol Photoimmunol Photomed. 2018 Jul;34(4):241-248
pubmed: 29381828
J Invest Dermatol. 2010 Aug;130(8):2092-7
pubmed: 20410914
Photodermatol Photoimmunol Photomed. 2014 Feb;30(1):35-42
pubmed: 24313385
Pigment Cell Melanoma Res. 2014 Sep;27(5):822-6
pubmed: 24888214
J Invest Dermatol. 2018 Jan;138(1):171-178
pubmed: 28842328